Global oncology company Novocure (Nasdaq:NVCR) said on Wednesday that it has entered into a clinical trial collaboration and supply agreement with biopharmaceutical company Verastem Oncology (Nasdaq:VSTM) to evaluate Tumor Treating Fields (TTFields) therapy combined with chemotherapy and Verastem's investigational KRAS G12D inhibitor, VS-7375, in patients with locally advanced pancreatic cancer.

Novocure plans to initiate a clinical trial involving approximately 25 patients to assess the safety and tolerability of TTFields alongside gemcitabine, nab-paclitaxel and VS-7375, with preliminary efficacy assessed as an exploratory endpoint.

Under the agreement, Novocure will manage and fund the clinical trial, while Verastem will supply VS-7375. Patient enrolment is expected to begin in 2027.

TTFields uses electric fields to target and kill cancer cells through multiple mechanisms. The therapy is being evaluated in combination with other treatment approaches for solid tumours.